Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.

ABSTRACT:

Context

Combination therapy with insulin and glucagon-like peptide-1 receptor agonists (GLP-1RAs) is important for treating type 2 diabetes (T2D). This trial assesses the efficacy and safety of semaglutide, a GLP-1RA, as an add-on to basal insulin.

Objective

To demonstrate the superiority of semaglutide vs placebo on glycemic control as an add-on to basal insulin in patients with T2D.

Design

Phase 3a, double-blind, placebo-controlled, 30-week trial.

Setting

This study included 90 sites in five countries.

Patients

We studied 397 patients with uncontrolled T2D receiving stable therapy with basal insulin with or without metformin.

Interventions

Subcutaneous semaglutide 0.5 or 1.0 mg once weekly or volume-matched placebo.

Main outcome measures

SUBMITTER: Rodbard HW 

PROVIDER: S-EPMC5991220 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature